Xenon Pharmaceuticals ROE 2012-2022 | XENE
Current and historical return on equity (ROE) values for Xenon Pharmaceuticals (XENE) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Xenon Pharmaceuticals ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2022-03-31 |
$-0.08B |
$0.54B |
-20.28% |
| 2021-12-31 |
$-0.08B |
$0.55B |
-23.12% |
| 2021-09-30 |
$-0.06B |
$0.25B |
-26.86% |
| 2021-06-30 |
$-0.06B |
$0.26B |
-26.19% |
| 2021-03-31 |
$-0.04B |
$0.28B |
-17.60% |
| 2020-12-31 |
$-0.03B |
$0.17B |
-15.34% |
| 2020-09-30 |
$-0.03B |
$0.18B |
-16.59% |
| 2020-06-30 |
$-0.03B |
$0.19B |
-19.85% |
| 2020-03-31 |
$-0.04B |
$0.19B |
-33.79% |
| 2019-12-31 |
$-0.04B |
$0.09B |
-47.95% |
| 2019-09-30 |
$-0.04B |
$0.08B |
-44.19% |
| 2019-06-30 |
$-0.04B |
$0.08B |
-44.22% |
| 2019-03-31 |
$-0.04B |
$0.09B |
-43.70% |
| 2018-12-31 |
$-0.03B |
$0.10B |
-43.69% |
| 2018-09-30 |
$-0.03B |
$0.11B |
-54.87% |
| 2018-06-30 |
$-0.03B |
$0.05B |
-65.82% |
| 2018-03-31 |
$-0.03B |
$0.03B |
-68.79% |
| 2017-12-31 |
$-0.03B |
$0.04B |
-66.67% |
| 2017-09-30 |
$-0.03B |
$0.04B |
-54.21% |
| 2017-06-30 |
$-0.03B |
$0.05B |
-48.33% |
| 2017-03-31 |
$-0.03B |
$0.06B |
-46.09% |
| 2016-12-31 |
$-0.02B |
$0.06B |
-37.70% |
| 2016-09-30 |
$-0.02B |
$0.07B |
-34.85% |
| 2016-06-30 |
$-0.02B |
$0.05B |
-28.81% |
| 2016-03-31 |
$-0.01B |
$0.06B |
-16.19% |
| 2015-12-31 |
$-0.02B |
$0.06B |
-25.40% |
| 2015-09-30 |
$-0.00B |
$0.06B |
-4.55% |
| 2015-06-30 |
$0.01B |
$0.06B |
8.51% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.548B |
$0.018B |
|
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
|
